Kelun Group Sustainability Profile
Kelun Group, officially known as Kelun Pharmaceutical Co., Ltd., is a prominent player in the pharmaceutical industry, headquartered in China (CN). Founded in 2004, the company has rapidly expanded its operations across major regions, including Asia, Europe, and North America, establishing a strong global presence. Specialising in the research, development, and manufacturing of high-quality generic and innovative drugs, Kelun Group is recognised for its commitment to advanced biopharmaceuticals and injectable products. The company’s unique approach to drug formulation and production has positioned it as a leader in the market, with notable achievements in regulatory compliance and product quality. With a focus on enhancing healthcare solutions, Kelun Group continues to make significant strides in the pharmaceutical sector, contributing to improved patient outcomes worldwide.
DitchCarbon Score
How does Kelun Group's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kelun Group's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kelun Group's reported carbon emissions
In 2024, Kelun Group reported total carbon emissions of approximately 2.845 billion kg CO2e, comprising about 2.362 billion kg CO2e from Scope 1 and approximately 484 million kg CO2e from Scope 2 emissions. The previous year, 2023, the total emissions were about 2.659 billion kg CO2e, with Scope 1 emissions at approximately 2.191 billion kg CO2e and Scope 2 emissions around 469 million kg CO2e. Kelun Group's emissions data is cascaded from its parent company, Sichuan Kelun Pharmaceutical Co., Ltd., indicating a corporate family relationship. However, there are currently no disclosed Scope 3 emissions or specific reduction targets from the Science Based Targets initiative (SBTi) or other climate pledges. The company has not outlined any formal reduction initiatives or commitments, which places it in a broader industry context where many organisations are increasingly focusing on sustainability and emissions reduction strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 2,190,590,170 | 0,000,000,000 |
| Scope 2 | 468,869,750 | 000,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Kelun Group's Industry?
How Carbon Intensive is Kelun Group's Location?
Kelun Group's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kelun Group has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
